Journal article

Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels

Amanda J Nicoll, Stuart K Roberts, Ricky Lim, Joanne Mitchell, Martin Weltman, Jacob George, Alan Wigg, Katherine Stuart, Paul Gow, Gerry MacQuillan, Edmund Tse, Miriam Levy, Siddharth Sood, Amany Zekry, Wendy Cheng, Jonathan Mitchell, Richard Skoien, William Sievert, Simone I Strasser, Geoffrey W McCaughan Show all

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | WILEY | Published : 2019

Abstract

BACKGROUND: Mycophenolate mofetil is a commonly used salvage therapy for patients with autoimmune hepatitis (AIH). AIM: To evaluate the predictors of response to mycophenolate rescue therapy to facilitate clinical decision making. METHODS: We performed a retrospective observational cohort study of AIH patients managed in 17 major Australian liver centres who received mycophenolate after an inadequate response or intolerance to corticosteroids with/without thiopurine(s). Baseline demographic, clinical and laboratory variables were compared between responders and nonresponders. A multivariable logistic regression model was developed using forward selection to identify independent predictors of..

View full abstract